Incyte Corporation

INCYintermediary

Incyte is a specialty biopharmaceutical company focused on oncology and inflammation, anchored by the blockbuster JAK inhibitor Jakafi and expanding into dermatology with Opzelura.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($3.9B)

Datos estáticos (cargando finanzas en tiempo real…)

Jakafi (55%)

Opzelura (18%)

Other Products (12%)

Royalties & Milestones (15%)

Composición de segmentos y clientes principales

Detalles del producto

Jakafi (ruxolitinib)55%

First-in-class JAK1/JAK2 inhibitor for myelofibrosis and GVHD

Opzelura (ruxolitinib cream)18%

Topical JAK inhibitor for atopic dermatitis and vitiligo

Monjuvi (tafasitamab)8%

Anti-CD19 antibody for diffuse large B-cell lymphoma

Royalties & Pipeline19%

Royalties from Pemazyre, Zynyz, and pipeline collaboration payments

Relaciones en la Cadena de Suministro

Competidores

Eli Lilly and Company

JAK inhibitor market (Olumiant)

Impacto: Medium — competing JAK inhibitors

AbbVie Inc.

JAK inhibitor market (Rinvoq)

Impacto: High — Rinvoq is major JAK competitor

Clientes Clave

Walgreens Boots Alliance

Specialty pharmacy distribution

Impacto: Medium — pharmacy channel

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Incyte Corporation impulsado por IA.

Información de la Empresa

Sede Central

Wilmington, Delaware, USA

Fundación

1991

Empleados

2,300+

Sitio Web

incyte.com

Estado del sector — 제약 / 바이오

Noticias del sector